Cytomegalovirus‐associated thrombocytopenia treated with thrombopoietin receptor agonist | Zendy

Simpson J. D. | Zendy; Matthews G. V. | Zendy; Brighton T. A. | Zendy; Joseph J. E. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cytomegalovirus‐associated thrombocytopenia treated with thrombopoietin receptor agonist

Author(s) -

Simpson J. D.,

Matthews G. V.,

Brighton T. A.,

Joseph J. E.

Publication year - 2016

Publication title -

internal medicine journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.596

H-Index - 70

eISSN - 1445-5994

pISSN - 1444-0903

DOI - 10.1111/imj.13181

Subject(s) - medicine , eltrombopag , cytomegalovirus , thrombopoietin , context (archaeology) , romiplostim , refractory (planetary science) , thrombopoietin receptor , immunology , agonist , immune thrombocytopenia , receptor , platelet , virus , herpesviridae , viral disease , haematopoiesis , biology , paleontology , genetics , stem cell , astrobiology

Symptomatic cytomegalovirus ( CMV ) in immunocompetent individuals is an uncommon, yet recognised, phenomenon. This report discusses a case of CMV ‐associated thrombocytopenia refractory to immunomodulation and antivirals. Ultimately, a clinicopathological response was attained with eltrombopag. This is the first report of the efficacy of thrombopoietin receptor agonists in this context. This experience provides insight into possible pathogenic mechanisms of CMV ‐associated thrombocytopenia and presents a therapeutic option.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research